--- title: "U.S. stock market quick update: JSPR down 9.07%! Analysts support KP-104, why is the market not buying it?" type: "News" locale: "en" url: "https://longbridge.com/en/news/295701344.md" description: "Jasper Therapeutics fell 9.07%; AbbVie fell 0.53%, with a transaction volume of USD 587 million; Gilead Sciences rose 0.37%, with a transaction volume of USD 477 million; Amgen rose 0.78%, with a transaction volume of USD 430 million; Fortress Biotech fell 0.37%, with a market capitalization of USD 133.7 billion" datetime: "2026-08-12T19:44:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295701344.md) - [en](https://longbridge.com/en/news/295701344.md) - [zh-HK](https://longbridge.com/zh-HK/news/295701344.md) --- # U.S. stock market quick update: JSPR down 9.07%! Analysts support KP-104, why is the market not buying it? **U.S. Stock Market Midday Update** JSPR fell 9.07%, with increased trading volume. Based on recent key news: 1. On August 12, analysts expressed confidence in the Phase 2 data of Jasper Therapeutics' KP-104 drug for PNH treatment, believing its long-term efficacy and safety are good, supporting further development in the nephrology field, and maintained a buy rating on JSPR. However, the market reaction was poor, leading to a decline in stock price. 2. On August 12, Benzinga released a rating action that may impact JSPR's stock price. 3. On August 12, ongoing macroeconomic uncertainty led investors to turn to safe-haven assets, resulting in capital outflows from JSPR, further exacerbating the decline in stock price. Macroeconomic uncertainty persists, with safe-haven assets in demand. **Stocks with High Trading Volume in the Industry** AbbVie fell 0.53%. Based on recent key news: 1. On August 10, AbbVie announced the acquisition of Apogee for $135.11 per share, totaling approximately $10.9 billion. This move aims to expand AbbVie's immunology product portfolio and attract more global patients, causing stock price volatility. 2. On August 11, BNP Paribas raised AbbVie's target price from $218 to $247. Analysts are optimistic about AbbVie's future performance, driving the stock price up. 3. On August 12, AbbVie's R&D investments and personnel-related costs increased, as the company added staff to advance the XTX501 and preclinical TCE projects, extending liquidity to the first quarter of 2028, affecting market expectations of its financial condition. The industry performed well overall, with significant capital inflows. Gilead Sciences rose 0.37%. Based on recent key news: 1. On August 4, Gilead Sciences reported a quarterly loss of $6.75 per share, better than analysts' expected loss of $7.24 per share. The company's quarterly sales were $7.803 billion, exceeding the expected $7.4 billion, driving the stock price up by 2%. 2. On August 11, Gilead Sciences reached an agreement with MacroGenics to pay $10 million for exclusive licensing of a bispecific project, enhancing market confidence. 3. On August 11, analysts raised Gilead Sciences' 2026 EPS estimate to -$0.45, with a target price of $163.50, boosting investor expectations. The biotechnology industry has performed strongly recently, with significant capital inflows. Amgen rose 0.78%, with a trading volume of $430 million. Based on recent key news: 1. On August 11, BeiGene announced that the jointly developed drug Antibody was officially put into clinical use with Amgen. This drug covers 80 cities nationwide and over 200 medical institutions, providing new treatment options for extensive-stage small cell lung cancer patients, driving Amgen's stock price up 2. On August 10, Amgen concentrated resources on developing the core dual-target project MariTide, covering multiple clinical projects including obesity and type 2 diabetes. The drug's long half-life and high compliance have raised market expectations, driving up the stock price. 3. On August 12, Amgen's annualized return over the past 15 years was 14.88%, significantly exceeding the market average. The long-term stable performance has enhanced investor confidence, pushing the stock price higher. The industry is active in innovative drug development, and market expectations are optimistic. **Stocks ranked at the top of the industry by market capitalization** Forte Pharmaceuticals fell 0.37%. Based on recent key news: 1. On August 10, Sionna Therapeutics' cystic fibrosis drug trial failed, causing its stock price to plummet by 92%. This event alleviated stock price pressure on Vertex Pharmaceuticals, driving its stock price up. Source: Barron's 2. On August 11, Jefferies raised the target price for Vertex Pharmaceuticals to $633, reflecting market confidence in its future performance. Source: Jefferies 3. On August 11, Sionna Therapeutics announced it would take measures to preserve capital and evaluate next steps. This move further solidified Vertex Pharmaceuticals' market position. Source: Barron's The biotechnology industry has been quite volatile recently and requires attention ### Related Stocks - [JSPR.US](https://longbridge.com/en/quote/JSPR.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) ## Related News & Research - [Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln](https://longbridge.com/en/news/295952283.md) - [Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | JSPR Stock News](https://longbridge.com/en/news/295951622.md) - [Scott Galloway says GLP-1 drugs are a 'silver bullet' for America's woes, if we're not 'stupid enough' to get in the way](https://longbridge.com/en/news/295999435.md) - [Argenx Shares Rise After Positive Results From Phase 3 Study of Efgartigimod](https://longbridge.com/en/news/296077357.md) - [The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech | NTHI Stock News](https://longbridge.com/en/news/295833253.md)